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Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with no clinically proven 
biologically targeted treatment options. The molecular heterogeneity of TNBC and lack of high 
frequency driver mutations other than TP53 have hindered the development of new and effective 
therapies that significantly improve patient outcomes. MicroRNAs (miRNAs), global regulators of 
survival and proliferation pathways important in tumor development and maintenance, are 
becoming promising therapeutic agents. We performed miRNA-profiling studies in different 
TNBC subtypes to identify miRNAs that significantly contribute to disease progression. We found 
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that miR-34a was lost in TNBC, specifically within mesenchymal and mesenchymal-stem cell like 
subtypes, whereas expression of miR-34a targets were significantly enriched. Furthermore, 
restoration of miR-34a in cell lines representing these subtypes inhibited proliferation and 
invasion, activated senescence, and promoted sensitivity to dasatinib by targeting the proto-
oncogene c-SRC. Notably, SRC-depletion in TNBC cell lines phenocopied the effects of miR-34a 
re-introduction, while SRC overexpression rescued the anti-tumorigenic properties mediated by 
miR-34a. miR-34a levels also increased when cells were treated with c-SRC inhibitors, suggesting 
a negative-feedback exists between miR-34a and c-SRC. Moreover, miR-34a administration 
significantly delayed tumor growth of subcutaneously and orthotopically implanted tumors in 
nude mice, and was accompanied by c-SRC downregulation. Finally, we found that miR-34a and 
SRC levels were inversely correlated in human tumor specimens. Together, our results 
demonstrate that miR-34a exerts potent anti-tumorigenic effects in vitro and in vivo, and suggests 
that miR-34a replacement therapy, which is currently being tested in human clinical trials, 
represents a promising therapeutic strategy for TNBC.
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Introduction
Triple-negative breast cancer (TNBC) comprises ~20% of breast cancers and accounts for a 
disproportionate share of morbidity because of its aggressive behavior, increased incidence 
in younger women, and lack of effective targeted therapies(1–4). This breast cancer subset is 
defined by what it lacks: estrogen-receptor, progesterone-receptor, and HER2 amplification, 
thereby limiting systemic treatment options for these patients to conventional chemotherapy. 
Transcriptional profiling studies initially suggested TNBC represented a distinct molecular 
entity that was different from ER-positive luminal-A type cancers(5). It has recently become 
apparent TNBC itself is a molecularly heterogeneous disease and is often subdivided into 
smaller categories including mesenchymal/mesenchymal stem cell-like (M/MSL), luminal 
androgen receptor type (LAR), and basal-like (BL) with or without an extensive 
immunomodulatory (IM) component(6–8). Despite identifying the molecular pathways 
dysregulated in TNBC, this extensive transcriptional and genomic heterogeneity has limited 
the development of broad therapeutic strategies for treating patients with TNBC. Therefore, 
discovery of a single therapeutic molecule that can function to suppress the multiple 
pathways supporting TNBC growth would be an important clinical breakthrough.
Since miRNAs target multiple pathways and function as signal modulators by fine-tuning 
gene expression to mediate tumor-suppressive phenotypes, these molecules represent 
attractive therapeutic options and targets. MiRNAs represent a class of small non-coding 
RNAs that function as global regulators of gene expression and are important master 
controllers of cell survival and proliferation pathways critically important in cancer 
development and tumor maintenance(9). These ~22 nucleotide, non-coding RNAs control 
the expression of protein coding genes via imperfect binding to the 3′ untranslated region 
(3′UTR) of the target messenger RNA (mRNA), leading to either translational inhibition or 
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degradation(10). Some studies estimate miRNAs regulate ≥60% of the human protein-
coding transcriptome(11). Importantly, single miRNAs can regulate entire cell signaling 
networks in a cell-context dependent manner(12). Since miRNAs can function as oncogenes 
or tumor suppressors, and can control the robustness of multiple cell signaling 
pathways(13,14), miRNAs that become dysregulated could promote a disease state, such as 
cancer. Our goal was to identify the key miRNAs dysregulated in TNBC in an effort to 
elucidate the disease and potentially point to novel miRNA-based therapeutics. We found 
miR-34a was selectively lost in TNBC cells and harbored tumor-suppressive functions when 
re-introduced into TNBC cells, with the most robust cell killing occurring in the 
mesenchymal-TNBC subtypes.
While there have been historical challenges associated with the use of RNA in therapy, 
chemical modifications to the backbone of synthetic RNA molecules in combination with 
advances in nanoparticle-based delivery methodologies, have resulted in significantly 
increased half-lives in vivo and better therapeutic potential. Lipid- and polymer-based 
nanoparticle systems can now be used to effectively deliver RNA molecules into tumor 
cells(15–18). Here we used a polyamine-co-ester terpolymer nanoparticle (tNP) technology, 
previously shown to actively target plasmid DNA to tumor cells(19), as a safe and effective 
method for delivering synthetic miR-34a into TNBC tumor cells in vivo. From the 
combination of our in vitro and in vivo studies, we found miR-34a ameliorates multiple 
tumor phenotypes, and acts through the regulation of mRNA targets such as BCL2, 
NOTCH1, and a novel target SRC. Moreover, this miR-34a effect occurs specifically in the 
mesenchymal-TNBC subtype, and can sensitize these cells to therapeutic agents such as 
dasatinib and paclitaxel.
Materials and Methods
Cell Culture
All breast cancer cell lines were purchased directly from ATCC in 2013 and maintained in 
DMEM supplemented with 10% FBS, 1% Pen/Strep and cultured at 37°C in a 5% CO2 
incubator. All experiments were performed within 6 months to 1 year upon receipt of cells, 
and characterization by STR analysis was performed by ATCC. Normal breast conditionally 
reprogramed cell lines (CRCs) were maintained without co-culturing with feeder cells(20). 
HMECs (Life Technologies) were maintained as per manufacture’s protocol, while 
MCF-10A cells were cultured in a defined media(21). For RNA-based functional 
experiments, mirVana mimics and validated Silencer Select siRNAs (Life Technologies) 
were transfected into 5×104 cells using DharmaFECT 1 (GE Healthcare Dharmacon), as per 
manufacture’s protocol. For extended experimental procedures see Supplementary Materials 
and Methods.
Quantitative Real Time PCR
For qPCR, cells were lysed in TRIzol (Life Technologies), and total RNA was used as the 
input for subsequent RT-PCR reactions. For miRNA analysis, cDNA synthesis and qRT-
PCR were performed according to the miScript II RT Kit (Qiagen) and miScript SYBR® 
Green PCR Kit (Qiagen) protocols respectively. For mRNA analysis, cDNA synthesis and 
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qRT-PCR were performed according to the RT2 First Strand Kit and RT2 qPCR Primer 
assay protocols (Qiagen).
Cell Viability
For assessment of cytotoxicity and development of IC50 curves, Sulforhodamine Blue (SRB) 
assays were performed as previously described(22), see Extended Experimental Procedures. 
For morphological assessments, cells were stained with 0.2% crystal violet for 10 min at 
room temperature, and washed with PBS. Images were acquired using a Zeiss dissection 
microscope (Zeiss, Jena, Germany), AxioCam MRc 5 camera (Zeiss) and AxioVision 4.7.1 
imaging software (Zeiss). In some instances, stained cells were treated with 10% acetic acid 
with 0.1% SDS and dye abundance was quantified by measuring absorbance at 600nm.
Invasion and Soft Agar Assays
For invasion assays, following miRNA or siRNA transfection, cells were cultured in 0.1% 
serum containing media overnight, and then seeded into BD BioCoat™ BD Matrigel™ 
Invasion Chambers. For soft agar assays, following miRNA or siRNA transfection, cells 
were mixed with agarose to a 0.3% concentration in RPMI growth media, and cultured for 
25 days. At the end of the study, inserts or cells were fixed, stained with crystal violet, and 
counted.
SA-β-Gal Assays
Following miRNA or siRNA transfection, cells were seeded into 12-well plates. After 5–6 
days, cells were assessed for cellular β-galactosidase activity, using a Senescence β-
Galactosidase Staining Kit (Cell Signaling Technology). Five randomly designated areas in 
each well were then scored for the proportion of cells containing a blue precipitate (cleaved 
X-gal) as compared to the total number of cells within the same field.
Animal Maintenance and Treatment
5- to 6-week-old female CrTac:NCr-Foxn1nu mice (Taconic) were maintained at Yale 
University in accordance with Yale Animal Resource Center and Institutional Animal Care 
and Use Committee guidelines. For tumor formation, miRNA treatments, and tumor analysis 
see Extended Experimental Procedures.
Luciferase Targeting Assays
For miRNA targeting assays, HEK-293T cells were transfected with a pLightSwitch-
SRC-3′UTR plasmid or an pLightSwitch-Empty-3′UTR control (SwitchGear Genomics), in 
combination with miR-34a or miR-Scr control using DharmaFECT Duo (GE Health 
Dharmacon). After 24 hours cells were lysed and luciferase activity measured as per 
manufacture’s protocol. Luciferase signal was normalized to the 0nM miRNA control 
condition for each UTR construct. Technical quadruplicates were performed and 
experiments were performed three times.
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Statistical Analysis
Unless otherwise stated, a student’s t test was used for p value calculations. Values reported 
are expressed as the mean ± SD, whereas densitometric readings of Western blot analyses 
are reported as averages. When more than one condition was being compared, such as 
changes between various treatments and control groups an ANOVA analysis was performed. 
Statistical significance was set at p<0.05.
Results
miR-34a is aberrantly lost and has prognostic value in TNBC
To identify miRNAs with potential therapeutic value in TNBC, we performed miRNA 
microarray analysis on >1000 miRNAs from 19 breast cancer cell lines. Clustering analysis 
of the top 50 most variant miRNAs indicated the presence of a subset of miRNAs 
differentially expressed between basal- and luminal-A type cell lines(Fig. S1A). qRT-PCR 
validation experiments were performed on a panel of 13 breast cancer and 9 normal breast 
cell lines to determine which miRNAs were differentially expressed as compared to normal 
cells. This included a set of conditionally reprogrammed cell (CRC) lines established from 
normal mammoplasty tissue(20). A number of highly expressed TNBC-specific miRNAs 
were identified, such as miR-221 and miR-155, when compared to luminal-A type cells, 
however these miRNAs were also highly expressed in CRC lines(Fig. S1B). Furthermore, 
non-tumorigenic MCF-10A and HMEC control lines also harbored high levels of these 
miRNAs.
Instead, we focused on identifying miRNAs lost in TNBC with the aim of pointing us 
towards a possible miRNA re-introduction-based therapeutic agent. We identified miR-34a 
and miR-200 to be aberrantly downregulated in TNBC cell lines as compared to both 
luminal-A type and normal breast cell lines(Figs. 1A & S1C). These findings support our 
previous work, where we identified miR-34a to be downregulated in TNBC breast cancer 
patient samples(23). Furthermore, miR-200 is a known regulator of metastatic processes, 
and is downregulated in TNBC(24,25). Given miR-34a is specifically lost in TNBC cell 
lines as well as in patient samples, and that the therapeutic targets of miR-34a specific to 
TNBC have not yet been well defined, we selected miR-34a for further investigation.
To determine if miR-34a harbored prognostic value in TNBC patients, Kaplan-Meier 
survival plots and Cox regressions were computed from TCGA. High expression of miR-34a 
in TNBC-patients conferred better overall survival (OS) (n=97, HR=0.22, p=0.041) than in 
those with low miR-34a, an effect not seen in the all-breast cancer patient cohort(Fig. 1B–
C). Given the heterogeneity of TNBC, we investigated whether predicted targets of miR-34a 
were enriched in specific TNBC subtypes. We returned to the original breast cancer cell line 
dataset where U133A data was available for 22,283 genes across 19 cell lines. We identified 
a TNBC-overexpressed gene-set (264 genes) which demonstrated enrichment for miR-34 
target genes(Fig. S1D). In addition, target enrichment of another TNBC-related miRNA, 
miR-200, was also identified. These miRNA targets were not enriched in the TNBC-under-
expressed gene-set (data not shown).
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We then performed hypergeometric analyses of all putative miR-34a targets across the 
TNBC subtype-specific gene expression (GE) profiles reported in Lehmann et al.(6). 3,000 
predicted miR-34a targets, irrespective of site conservation, were acquired from 
TargetScan(26), and compared to the top 20% upregulated genes within all TNBC (~2,872 
genes), and within each TNBC subtype (variable sample size). When the number of 
miR-34a-TNBC subtype-specific targets were compared to the total number of miR-34a-
TNBC targets, hypergeometric analysis indicated an overrepresentation of miR-34a targets 
present in the MSL-and M-TNBC subtypes, while miR-34a targets in the LAR and 
immunomodulatory (IM) TNBC subtypes were substantially underrepresented(Fig. 1D). A 
stringent enrichment analysis on 760 high confidence miR-34a targets was also performed, 
which still resulted in significant overrepresentation occurring within the MSL-TNBC 
subtype(Fig. S1E). These data support the notion that the genes important for growth and 
survival within mesenchymal-TNBC cell types are highly regulated by miR-34a, and that 
these cells suppress miR-34a to maintain a tumorigenic state.
miR-34a is a bona-fide TNBC tumor suppressor
To determine if miR-34a promoted tumor-suppressive phenotypes in TNBC, we transfected 
a panel of breast cancer cell lines with 30nM miR-34a or scrambled control (miR-Scr), and 
assayed cell growth using SRB assays(22). BT-549 and MDA-MB-231 TNBC growth was 
inhibited by miR-34a re-introduction(Fig. 1E), while luminal-A MCF-7, and LAR-TNBC 
MDA-MB-453 cells were marginally impacted. This TNBC-specific growth inhibition by 
miR-34a was observed in an extended panel of TNBC lines, while normal CRCs and human 
fibroblasts (HFF) were not severely impacted(Fig. S1F). Lower IC values were also 
obtained in TNBC lines versus luminal-A or LAR-50 TNBC cell lines(Table 1).
We next investigated additional anti-tumorigenic phenotypes associated with miR-34a 
reintroduction. The earliest phenotypic consequence, observed 36 hours after miR-34a 
transfection, was abrogation of invasion. Using Matrigel-coated Boyden-chamber assays, 
BT-549, MDA-MB-231, and MDA-MB-436 cells transfected with 5nM miR-34a resulted in 
~2.1-, 4.0-, and 2.9-fold reductions in the number of invasive cells(Figs. 2A & S2A). This 
phenotype is present prior to any anti-growth effects mediated by miR-34a, which occurs 
>84 hours post-transfection(Fig. 1E), and is not a result of apoptosis(Fig. 2C). These data 
suggest miR-34a regulates cellular targets in TNBC cells important in focal adhesion and 
invasion, which are the same signaling pathways that define MSL- and M-TNBC subtypes.
We next tested whether miR-34a transfected TNBC cells could grow in an anchorage-
independent fashion. Specifically, BT-549, MDA-MB-436, and MDA-MB-231 cells 
transfected with 7.5nM miR-34a resulted in ~8.2-, 4.1-, and 3.6-fold reductions in colony 
formation, respectively, after 20 days of culture in 0.3% soft agar(Figs. 2B & S2B). To 
determine if this phenotype was due to a block at a particular stage in cell cycle progression, 
we performed propidium-iodine (PI) staining assays, which indicated miR-34a transfected 
MDA-MB-231 cells resulted in a 5% increase of cells in G2/M 4–6 days post-
transfection(Fig. 2D). Similar results were obtained with BrdU assays(Fig. S2C). Despite 
this marginal G2/M arrest, miR-34a transfected TNBC cells underwent striking 
morphological changes indicative of senescence: specifically an elongated and flattened 
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cytoplasm(27)(data not shown). Senescent cells can be the result of both G1 and/or G2 
arrest(27), which may explain the lack of a stage-specific block in cell cycle upon miR-34a 
transfection. Indeed, SA-β-gal assays performed on miR-34a transfected TNBC cells 
confirmed this senescence-promoting effect in a dose-dependent manner(Figs. 2E & S2D–
E). Conversely, MCF-7 cells, which harbor high endogenous miR-34a levels and higher 
baseline rates of senescence, had an ~2-fold reduction in SA-β-gal activity when treated with 
a miR-34a sponge(Fig. S2F).
To determine whether miR-34a-induced anti-tumorigenicity was due to differential 
transfection efficiencies, we performed psiCheck2 luciferase reporter assays, where a 
miR-34a sensor sequence was inserted downstream of Renilla luciferase. Co-transfection 
experiments using wild-type or mutant sensors and miR-34a or miR-Scr mimics indicated 
500pM miR-34a was sufficient to reduce reporter activity by 5–10-fold across all lines 
tested(Fig S2G). Therefore, the anti-tumorigenic phenotype induced by 5–30nM of miR-34a 
in MSL- and M-TNBC cells likely reflects a heightened sensitivity to miR-34a re-
introduction and not differential transfection efficiency. Overall these data suggest miR-34a 
re-introduction in TNBC shuts down oncogenic signaling pathways that affect invasion and 
proliferation, eventually resulting in cell death by way of cytostasis/senescence. 
Interestingly, some oncogenic mediators could include non-coding RNAs such as the 
miR-17/92 cluster, which is known to be elevated in TNBC(28–30) and can be 
downregulated by miR-34a reintroduction(Fig. S2H).
Systemic delivery of miR-34a has tumor-suppressor activity in vivo
Given the in vitro findings, we tested whether miR-34a could reduce tumor growth in vivo. 
MDA-MB-231 cells were mixed with Matrigel and injected into the flanks of CrTac:NCr-
Foxn1nu mice. Once tumors reached 150mm3, mice were randomized into a miR-34a or 
miR-Scr treatment cohort. MiRNA mimics were packaged into a neutral-lipid emulsion and 
injected intratumorally at a 25μg/tumor dose. After 3 treatments, given every four days, 
miR-34a tumors did not proliferate beyond pre-treatment tumor size, while miR-Scr tumors 
grew unperturbed(Fig. 3A; left panel). At the end of the study, tumors treated with miR-34a 
harbored an ~4.4-fold reduction in tumor weight, as compared to miR-Scr controls(Fig. 3A; 
right panel).
To test if systemic delivery of miR-34a could impact the progression of TNBC, MDA-
MB-231 tumors, originally inoculated at the orthotopic mammary site were treated 
systemically with tNP-packaged miR-34a or miR-Scr control. After 3 treatments of a 
1.5mg/kg dose every 4 days, mice given miR-34a had significantly reduced tumor 
growth(Fig. 3B). Tumors were harvested for further analysis, and while tumor weights were 
only slightly decreased in the miR-34a arm, a marked reduction in Ki67 staining was 
observed when compared to controls(Fig. 3E). MiR-34a levels were elevated ~2.5-fold in 
the miR-34a treated tumors(Fig. 3C), while bona-fide miR-34a targets such as JAG1 were 
downregulated(Fig. 3D). Taken together, these data indicate tNP can deliver functionally 
active miR-34a to tumors located at the mammary orthotopic site, resulting in miRNA-
mediated phenotypes in vivo. To assess toxicity associated with systemic delivery of 
miR-34a, we collected serum from mice given miR-Scr and miR-34a treatments. Liver 
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function tests showed no evidence of hepatic damage(Fig. 3F). Liver tissue architecture was 
also normal, and we did not find any evidence for TUNEL+ cells(Fig. 3G).
miR-34a can sensitize mesenchymal-TNBC cells to dasatinib
We next tested whether miR-34a could sensitize TNBC cells to certain front-line agents for 
TNBC patients. Using clonogenic assays, we found 10nM miR-34a induced variable 
sensitivities to 0.15–4nM paclitaxel in MDA-MB-231, BT-549, MDA-MB-453, and Hs578T 
cells(Figs. 4A–C & S3B). Although significant, this was a mild sensitization effect. Instead, 
given miR-34a has strong anti-tumorigenic effects in the MSL- and M-TNBC subtypes, and 
that these subtypes are sensitive to agents such as dasatinib due to heightened expression of 
focal adhesion genes such as c-SRC(6)(Fig. S3A), we tested whether miR-34a could 
synergize with dasatinib in TNBC cells. Indeed, 10nM miR-34a sensitized MDA-MB-231, 
BT-549, Hs578T, and MDA-MB-436 cells to 11–900nM dasatinib, as compared to miR-Scr 
control(Figs. 4A–B & S3B–C). We did not observe this sensitivity in the LAR-TNBC 
MDA-MB-453 cells or in HeLa cells(Figs. 4C & S3C), giving credence to the notion that 
miR-34a synergizes with dasatinib by regulating similar pathways important to the biology 
of mesenchymal-TNBC cells.
Given this miR-34a-dasatinib synergy, we wondered whether dasatinib could affect 
endogenous miR-34a levels in TNBC. MDA-MB-231 cells treated with dasatinib for 60 
hours demonstrated a dose-dependent increase in miR-34a levels, with the highest fold-
change being 4.4-fold in 100nM treated cells as compared to the 0nM control(Fig. 4D). This 
effect appeared selective given miR-15a levels did not change more than 1.7-fold across any 
treatment condition. Dasatinib-induced miR-34a was functional as it resulted in reduced 
miR-34a sensor reporter activity(Fig. 4E), and levels of miR-34a targets such as JAG1(31)
(Fig. S3D). These effects are dasatinib-specific, as paclitaxel treated MDA-MB-231 cells 
showed no significant increase in miR-34a levels, even at cytotoxic levels ≥1nM(Fig. S3E). 
While the mechanism(s) by which dasatinib-mediated induction of miR-34a levels occur(s) 
is unclear, given dasatinib is a c-SRC inhibitor, c-SRC signaling could regulate activity of a 
transcription factor or an RNA binding protein that controls expression, stability and 
turnover of miR-34a. Since we observed no active luciferase expression generated from 
reporters containing previously described miR-34a promoters(32)(Fig. S3F), this indicates 
that dasatinib-mediated induction of miR-34a was not transcriptional.
If part of the anti-tumorigenic property of dasatinib is through enhancement of miR-34a 
activity, then a dasatinib resistant line (MDA-MB-231-DasR cells; Fig. 4F), which has an 
abrogated response to dasatinib, should harbor lower levels of miR-34a and have weaker 
miR-34a dasatinib-associated cytotoxicity. Indeed, MDA-MB-231-DasR cells harbored 3.9-
fold lower levels of miR-34a in the presence of 200nM dasatinib(Fig. 4H). Additionally, in 
our clonogenic model, 1μM dasatinib alone killed ~75% of the MDA-MB-231-DasR 
cells(Fig. 4G), whereas ~95% kill is observed in parental cells at this dosage. Furthermore, 
while addition of miR-34a did sensitize the MDA-MB-231-DasR cells to dasatinib, the 
effect was milder, with upwards of 15nM miR-34a and 1μM dasatinib required to evoke a 
90% kill (Fig. 4G). This value was 98% in parental MDA-MB-231 cells using 10nM 
miR-34a + 300nM dasatinib. Despite these subtleties, miR-34a significantly sensitized both 
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parental TNBC and DasR cells to dasatinib. Given that clinical trials utilizing dasatinib in 
combination with front-line chemotherapeutic agents such as paclitaxel are still ongoing for 
patients with metastatic breast cancer (NCT00820170 and NCT00924352), we conjecture 
that addition of a miR-34a agent to these experimental treatment regimens would result in 
significantly higher response rates.
miR-34a targets the mesenchymal-TNBC specific proto-oncogene c-SRC
Given that dasatinib is a c-SRC inhibitor, the finding that dasatinib promotes miR-34a levels 
while concomitantly reducing c-SRC levels(Fig. S3D), suggests c-SRC in mesenchymal-
TNBC cell lines may be part of a feedback loop where c-SRC dampens miR-34a expression 
and miR-34a directly targets and represses c-SRC(Fig. S3J). While there was an inverse 
correlation between miR-34a and c-SRC levels in vitro(Figs. 1A, S3A, & S3G), we wanted 
to determine whether this occurred in tumor samples. We assessed Metabric data, since 
Illumina mRNA- and Agilent miRNA-microarray data are available on 1,262 patient 
samples. Spearman rank correlation analysis identified anti-correlation between SRC and 
miR-34a levels (rho=−0.064; n=1262; p<0.008; Fig. S3H). TCGA data was also assessed, 
however we found no significant anti-correlation (rho=−0.01; p=0.33), which may be due to 
the smaller sample size (n=632).
We then looked for miR-34a target sites within the SRC 3′UTR using miRNA prediction 
algorithms and found three putative target sites(Fig. 5A). We performed 3′UTR luciferase 
targeting assays whereby the SRC 3′UTR was cloned into pLightSwitch. Co-transfection 
experiments in HEK-293T cells indicated a dose-dependent reduction in luciferase activity 
in miR-34a transfected cells(Fig. 5B). This effect was not observed on an Empty-3′UTR 
control or in miR-Scr control transfected cells. Additional mutational analysis of the SRC 
3′UTR by Muppala et al.(33), indicated that miR-34a-induced repression of SRC 3′UTR 
luciferase activity was predominately mediated by the middle miR-34a binding site depicted 
in Figure 5A, which is also the most conserved out of the three target sites according to 
TargetScan. Importantly, 72 hours post-miR-34a transfection, MDA-MB-231, MDA-
MB-436, and BT-549 cells harbored 5.6-, 2.0-, and 4.4-fold reductions in SRC transcript 
levels, respectively(Fig. 5C). Reductions in c-SRC protein expression, as well as the SRC-
regulated gene β-catenin, were also observed in miR-34a transfected TNBC cells but not in 
luminal-A MCF-7 cells(Fig. 5D). Additionally, miR-34a treated MDA-MB-231-derived 
tumors from our orthotopic experiments harbored ~1.9-fold reduced SRC levels (p≤0.049), 
as compared to miR-Scr treated tumors(Fig. 5E). Taken together, these results indicate 
miR-34a and c-SRC are part of a regulatory feedback loop in TNBC cells, whereby 
enhanced activity of c-SRC results in the concomitant repression of miR-34a, and yet does 
not appear to involve upstream kinases since the pTyr-416/SRC ratio was not altered by 
miR-34a re-introduction(Fig. S3I).
Loss of c-SRC in mesenchymal-TNBC cells phenocopies gain of miR-34a
Given these results, loss of c-SRC should result in a phenocopy of the gain of miR-34a in 
TNBC cells. Indeed, MDA-MB-231 cells transfected with 15nM si-SRC promoted a strong 
anti-growth and pro-senescent phenotype(Figs. 5F–H), similar to miR-34a transfected cells. 
No effects were observed in 15nM si-Neg control treated cells. This ≥2.5-fold anti-growth 
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phenotype induced by 15nM si-SRC was also observed in additional TNBC lines(Figs. 5H 
& S4A–B), and when using a second c-SRC siRNA(Fig. S4C). In normal HFF fibroblasts, 
SRC knockdown resulted in only a 1.3-fold reduction in cell growth as assayed by crystal 
violet(Figs. S4D). si-SRC transfected TNBC cells also had ~2-fold higher miR-34a levels as 
compared to si-Neg transfected cells(Figs. 5J & S4F), confirming the negative regulatory 
actions of c-SRC on miR-34a, as highlighted by the dasatinib experiments. SRC knockdown 
efficiency experiments confirmed si-SRC transfected TNBC cells resulted in ~5-fold or 
greater reductions in SRC mRNA levels(Fig. S4G), as well as significant reductions in c-
SRC protein levels(Fig. 5I & S4C). When senescence assays were performed in si-SRC-
transfected MDA-MB-231 cells we observed a 3.6-fold increase in β-gal positive cells(Fig. 
5G). In an extended panel of si-SRC-transfected TNBC lines the effects were not as 
robust(Fig. S4E), suggesting loss of a single miR-34a target is not sufficient to induce 
cytostasis, and that miR-34a regulates multiple proto-oncogene targets in TNBC cells to 
induce pro-senescent phenotypes.
MDA-MB-231 SRC-ORF lines are less responsive to miR-34a re-introduction
Given that c-SRC is an important proto-oncogene in TNBC regulated by miR-34a, we 
performed gain-of-function rescue experiments to directly assess the contribution of c-SRC 
in miR-34a-mediated tumor suppression. We generated stable MDA-MB-231-SRC-ORF-
GFP overexpressing cell lines through lentiviral transduction. Here, c-SRC is expressed 
from an RNA transcript without its native 3′UTR, and therefore is not under the regulatory 
control of miR-34a, as we computationally determined potential miR-34a binding sites 
across the entire SRC transcript via RNAhybrid(34), and found none within the coding 
region. SRC mRNA levels were >40-fold in the SRC-ORF-GFP lines as compared to a 
control MDA-MB-231-Empty-GFP overexpressing line, or parental MDA-MB-231 
cells(Fig. S5A). SRC protein expression was elevated only ~3.0-fold in the SRC-ORF-GFP 
lines as compared to parental MDA-MB-231 cells(Fig. 6A). This mild overexpression of c-
SRC is expected, given persistently high levels of c-SRC results in severe cytotoxicity(35), 
and is supported by our observation that GFPhigh cell populations cannot be maintained in 
culture. This also indicates the SRC-ORF-GFP line expresses c-SRC at physiologically 
appropriate levels. This c-SRC is functional, given we observed morphological changes in 
these cells including greater frequency of cell rounding accompanied by similar rates of cell 
growth, as has been reported by others(35). We also observed reduced miR-34a levels in the 
SRC-ORF-GFP line(Fig. 6E), expected given our findings that c-SRC negatively regulates 
miR-34a.
We performed several functional tests in the presence of exogenous miR-34a or miR-Scr 
control, to determine if SRC-ORF-GFP cells were resistant to miR-34a effects. SRB assays 
indicated growth of Empty-GFP cells after miR-34a transfection was reduced 3.4-fold, as 
compared to miR-Scr control treatment(Fig. 6B). However, SRC-ORF-GFP cells only 
harbored an ~1.5-fold reduction in growth post-miR-34a transfection(Figs. 6B & S5B). 
SRC-ORF-GFP lines were also protected from the effects of miR-34a in soft agar assays. 
SRC-ORF-GFP cells underwent colony formation with greater efficiency than Empty-GFP 
lines, as determined by the 1.3-fold increase in colony number(Fig. 6C), and by the 
increased colony size. While miR-34a transfection resulted in a 3.5-fold decrease in colony 
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formation in the Empty-GFP line, miR-34a induced only an ~1.3-fold decrease within the 
SRC-ORF-GFP line. Therefore we conclude overabundance of c-SRC prevents miR-34a-
meditated inhibition of anchorage-independent cell growth.
We next tested whether SRC-ORF-GFP lines had a blunted response to the effects of 
miR-34a on cell invasion(Fig. 6D). Similar to parental MDA-MB-231 cells, Empty-GFP 
lines transfected with miR-34a resulted in a 2.4-fold inhibition of invasion. At baseline, 
SRC-ORF-GFP cells had ~2.5-fold greater rates of invasion than Empty-GFP cells, as 
would be expected given the pro-migratory phenotypes conferred by c-SRC through 
activation of FAK, RhoA, and PAK signaling(36). However, miR-34a only conferred a 1.2-
fold reduction of invasion in the SRC-ORF-GFP cells, indicating gain of c-SRC expression 
dampens the anti-invasive effects of miR-34a. Overall, these rescue experiments indicate 
miR-34a regulation of c-SRC partly contributes to the anti-growth effects, but to the 
majority of the anti-invasive phenotypes mediated by miR-34a re-introduction into TNBC 
cells.
Identification of a miR-34a gene signature with prognostic value in TNBC
Given the strong anti-tumorigenic effects of miR-34a within TNBC cells in vitro and in vivo, 
we asked whether a miR-34a target gene signature could be used as prognostic indicator for 
TNBC. MDA-MB-231, BT-549, and MDA-MB-436 cells were transfected with either 
miR-34a or miR-Scr control for 72 hours, and qPCR breast cancer array experiments were 
performed on RNA isolates(Fig. 6F). Since MDA-MB-436 and BT-549 cells were highly 
correlated with each other(Fig. S5C), they were used in the subsequent K-Means clustering 
analysis(Fig. S5D). This analysis identified 4 gene-clusters. Clusters 2 and 3 were most 
affected by miR-34a re-introduction, since 40–56% of these genes were downregulated ≥2-
fold on the qPCR array(Fig. S5E). KEGG pathway analysis indicated that 16 out of the 50 
genes in Clusters 2 and 3 were involved in “focal adhesion”(Fig. S5F), intriguing given 
mesenchymal-TNBC subtypes harbor a gene expression pattern that includes elevated focal 
adhesion pathways. Furthermore, in the original hypergeometric analysis, putative miR-34a 
targets were found to be overrepresented in MSL-and M-TNBC subtypes. This clustering 
and KEGG analysis indicates that miR-34a re-introduction in these cell lines reduces the 
expression of focal adhesion genes important in mesenchymal-TNBC biology.
To identify a robust miR-34a gene signature, we asked if the miR-34a downregulated genes 
identified in Clusters 1–4 were also downregulated in a third cell line, MDA-MB-231, upon 
miR-34a re-introduction. Using a 2-fold cutoff criterion, seven genes emerged; BCL2, 
GRB7, IGF1R, JAG1, KRT18, NOTCH1, and SRC as being consistently downregulated 
across 3 separate TNBC lines(Fig. 6G). Three of these genes, BCL2, JAG1, and NOTCH1, 
are known direct targets of miR-34a(37), while the novel miR-34a target c-SRC discovered 
in this work was part of this signature as well. Data obtained from Metabric indicated all 7 
genes were inversely correlated with miR-34a in TNBC patients (n=203), albeit with some 
variability in significance(Fig. S5G). More important is the finding that this seven-gene 
signature harbors prognostic value. Using the KM-plotter tool, capable of evaluating 
survival in 4,142 breast cancer samples(38), we found high expression of these miR-34a 
targets confers a worse overall survival(Fig. 6H). This effect was stronger in TNBC patients 
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(n=245, HR=3.3, p=0.00002) compared to those with Luminal-A tumors (n=611, HR=1.7, 
p=0.005). The prognostic impact of this gene signature was further validated using a 
PROGgeneV2 algorithm on TCGA breast cancer data(Fig. S5H). Overall, our data supports 
the idea that re-introduction of miR-34a in mesenchymal-TNBC cell lines promotes anti-
tumorigenic phenotypes largely by targeting the proto-oncogene SRC.
Discussion
In this study, we show miR-34a is dysregulated in TNBC, and when re-introduced can 
promote tumor-suppressive effects both in vitro and in vivo. Furthermore, we demonstrated 
that miR-34a replacement could successfully be performed using tNP technology as a 
delivery method in mouse xenograft models. MiR-34a imparts these phenotypic effects by 
targeting SRC as well as other bona-fide targets such as BCL2 and NOTCH1(39). Moreover, 
since a double-negative feedback loop exists between c-SRC and miR-34a, TNBC cells can 
be sensitized to the c-SRC inhibitor dasatinib after miR-34a re-introduction.
miR-34a belongs to the miR-34 family of miRNAs: miR-34a, miR-34b, and miR-34c. 
MiR-34a is located at 1p36 and is encoded in its own transcript, whereas miR-34b and 
miR-34c share a primary transcript on 11q23(40). All of these miRNAs share the same seed 
sequence, and therefore have similar endogenous mRNA targets. The expression of miR-34b 
and miR-34c is low across all breast cancers, due to allelic deletions and/or the loss of 
heterozygosity that frequently occurs at 11q23(41,42). Additionally, miR-34a can be 
epigenetically regulated through promoter hypermethylation in some breast cancer cell lines 
and human tumor specimens(43,44). Given the small sample size of these studies, it is still 
difficult to conclude whether aberrant methylation of miR-34a plays a predominate role in 
TNBC.
MiR-34a is well established to be under the transcriptional control of the TP53 tumor-
suppressive network(45–47). TP53 directly binds the mir-34a promoter inducing its 
expression, while miR-34a indirectly promotes p53 expression by targeting and repressing 
levels of the deacetylase SIRT1, which negatively regulates TP53. Given this positive feed-
forward regulatory loop, tumors harboring wild-type TP53 have higher levels of miR-34a 
than tumors containing a TP53 mutant allele. Since many TNBC cell lines and tumors 
harbor TP53 inactivating mutations, or are TP53 null, it is not surprising we observed a 
striking reduction in miR-34a levels within these cell lines and patient samples.
We found both dasatinib and siRNA to c-SRC resulted in enhanced miR-34a levels and 
activity in TNBC cells. We did not observe similar changes when cells were treated with 
paclitaxel, and found no evidence for SRC-mediated transcriptional regulation of miR-34a. 
Furthermore, SRC-ORF overexpressing MDA-MB-231 cells harbored ~2-fold lower 
miR-34a levels. Together, these data suggest c-SRC, which is highly expressed in TNBC, 
results in the post-transcriptional dampening of miR-34a levels. Further investigation will be 
required to decipher the post-transcriptional mechanism by which c-SRC controls miR-34a 
turnover or decay in TNBC cells. However, since c-SRC can promote PI3K/AKT signaling, 
miR-34a levels may be controlled by the PI3K/AKT/MDM2 signaling as suggested by 
Silber et al.(48).
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We also found miR-34a directly targets c-SRC within its 3′UTR. Re-introduction of 
miR-34a into TNBC cells significantly reduced SRC mRNA levels both in vitro and in vivo, 
as well as c-SRC protein levels in vitro. These data suggest miR-34a and c-SRC form a 
double-negative-feedback regulatory loop(Fig S3J). Numerous miRNA-mRNA regulatory 
loops have been identified, and function as an essential regulatory unit that controls the fine-
tuning of gene expression important in proper developmental processes(14). In cancer, these 
feedback loops can become dysregulated, allowing for a permissive tumorigenic state. In our 
study, it appears mesenchymal-TNBC cells harboring elevated levels of c-SRC exhibit 
reduced levels and activity of miR-34a. This may explain why miR-34a re-introduction was 
able to specifically sensitize mesenchymal-TNBC cells to dasatinib treatment, while it 
promoted a marginal sensitization to paclitaxel. Furthermore, the impact of miR-34a when 
re-introduced as a stand-alone agent specifically within the mesenchymal-TNBC subtype 
was quite striking. Consistent with this effect, hypergeometric analysis indicated MSL- and 
M-TNBC cells highly express genes that are putative miR-34a targets, more so than other 
TNBC-subtypes. Overall, these data suggest the pathways aberrantly overexpressed in 
mesenchymal-TNBC cells important in supporting a pro-tumorigenic state, can also be 
suppressed by miR-34a, and is why miR-34a levels are found at an extremely low steady-
state in these cancers.
Overall, we observed a robust anti-growth, anti-invasion, and pro-cytostatic phenotype 
occurring in TNBC cells transfected with miR-34a. This complete shutdown of the pro-
tumorigenic network indicates numerous genes essential for tumor survival are being 
downregulated by miR-34a. For instance, we observed downregulation of canonical targets 
such as BCL2, NOTCH1, and IGF1R(39,49). As highlighted in Figure 6I, many of these 
miR-34a targets were also embedded within the c-SRC signaling pathway, including SRC 
itself, which is activated by integrin and focal adhesion kinase (FAK) signaling. 
Interestingly, GRB7, an adaptor protein important in mediating FAK/SRC signaling was also 
downregulated by miR-34a in TNBC cells. This effect is predicted to result in a dampening 
of downstream MAPK and PI3K/AKT signaling pathways important for growth and 
survival. In support of this, miR-34a treated cells displayed decreases in AKT-regulated 
genes such as BCL2 and β-catenin, which are known to be elevated by c-SRC(50). Even the 
established miR-34a target NOTCH1 can be controlled by c-SRC during an important 
processing step involving c-SRC-induced Furin-mediated S1 cleavage of NOTCH1 in the 
trans-Golgi network(51).
Given the multi-gene targeting occurring in TNBC cells, and from our in vitro and in vivo 
data, we conclude that miR-34a could be a promising therapeutic agent for treating TNBC 
patients. Recently, there has been a major effort to develop small RNAs into therapeutic 
agents(22,52,53). Our observations are clinically relevant because an amphoteric liposomal 
formulation complexed with a synthetic miR-34a mimic (MRX34) is currently being tested 
in a Phase I clinical trial for patients with hepatocellular carcinoma(54). In pre-clinical 
models, MRX34 inhibited tumor growth of Hep3B or HuH7 cells orthotopically implanted 
into the livers of NOD/SCID mice(17). Given miR-34a can target c-SRC and sensitize 
TNBC cells to dasatinib, our data suggest that the combination of a miR-34a-based 
therapeutic with dasatinib is worth exploring in future clinical studies of TNBC.
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Figure 1. miR-34a is aberrantly expressed in mesenchymal-TNBC and is prognostic
A, qPCR analysis of miR-34a levels in normal breast (gray), Luminal-A cancer (blue), Basal 
cancer (red) cell lines. B and C, Kaplan-Meier and Cox-regression analysis of miR-34a 
levels and overall survival in TNBC (B) or all (C) breast cancer patients from TCGA 
datasets. D, Hypergeometric analysis(55) of miR-34a targets present within each TNBC-
subtype as compared all highly expressed TNBC genes. Specifically, Venn diagrams depict 
the top 20% most abundant TNBC genes (yellow) and TNBC-subtype genes (green) from 
Pietenpol et al.(6) as compared to all putative miR-34a targets (red). Table depicts the 
number of miR-34a targets in all TNBC (Number of Successes in Population), and in each 
TNBC subtype (Number of Successes in Sample), along with the probabilities of success. 
The probabilities of having X number, or >X number of miR-34a target sites within each 
TNBC subtype and compared to all TNBC are reported. P<0.05 was considered significant. 
E, SRB growth curves, where various cell lines were transfected with 30nM miR-34a and 
assayed at indicated times for enumerating cell abundance. SRB assays were performed 
three independent times with error bars reflecting SEM for each condition or time point 
analyzed. P-values were calculated by two-way ANOVA.
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Figure 2. miR-34a is tumor-suppressive and promotes cytostasis in mesenchymal-TNBC cells
A, BT-549 and MDA-MB-231 cells were transfected with indicated amounts of miR-Scr or 
miR-34a mimic, serum starved, and plated into Matrigel-coated Boyden chambers with 5% 
serum as the chemo-attractant. Values reported are the average number of invaded cells 
counted per field. B, BT-549 and MDA-MB-231 transfected cells were seeded into 0.3% 
soft agar and after 25 days the number of colonies were counted. C, MDA-MB-231 
transfected cells (30nM miRNA) were treated with either 20μM Camptothecin, 0.1% DMSO 
vehicle, or left untreated, and stained with FITC-VAD-FMK to detect the percentage of 
apoptotic cells. MiR-34a cells have a heightened percentage of cells undergoing active 
caspase cleavage only when concomitantly provided Camptothecin, a quinolone alkaloid 
known to induce apoptosis. Values under each FACS plot indicate average number or 
apoptotic events per condition +/− SEM. D, MDA-MB-231 transfected cells at indicated 
times and dose were stained with PI for cell cycle analysis. Numbers in bar graphs represent 
average percent of cells within each stage of cell cycle, and as a fraction of the total 
population within each condition. E, MBA-MB-231 cells, 6 days post-transfection were 
stained with SA-β-Gal. Presence of blue perinuclear staining emerged in the miR-34a 
condition (left panel), which is quantified as an average number of SA-β-Gal positive cells 
from three independent experiments +/-SEM (right panel). * Indicates p<0.01, as compared 
to control conditions.
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Figure 3. tNP-packaged miR-34a nanoparticles harbor therapeutic efficacy in vivo
A, CrTac:NCr-Foxn1nu mice containing subcutaneously implanted MDA-MB-231 cells 
embedded in Matrigel were treated intratumorally with NLE-packaged miR-34a or miR-Scr 
control particles at a 25μg/tumor dose (left panel). Green arrows indicate treatment times. At 
end of study tumor weights were collected (right panel). All data are depicted as an average 
tumor size from 8 mice +/− SEM. B, CrTac:NCr-Foxn1nu mice containing orthotopically 
implanted MDA-MB-231 cells were treated with tNP-packaged miR-34a or miR-Scr control 
particles. Green arrows indicate times at which mice were given tail vein injections of 
miRNA-tNP particles at a 1.35mg/kg dose. Tumor weights are depicted in right panel. All 
data are depicted as an average tumor size from 8 mice +/− SEM. C and D, miRNA (C) and 
target mRNA (D) analysis of tumor RNA from each treatment cohort in the miRNA-tNP 
trial, n=6, ** indicates p<0.05. E, Representative H&E (top) and Ki67 (bottom) staining 
images from treated mice; scale bars, 100μm. Ki67 staining is depicted as an average score 
(n=6). F and G, MiRNA toxicity studies. Liver panel analysis on mouse serum from each 
miRNA-tNP treatment cohort (n=5) (F), and representative images of liver tissue stained 
with H&E (top) and TUNEL (bottom); scale bars, 100μm (G). 
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Figure 4. miR-34a sensitizes mesenchymal-TNBC cells to dasatinib
A–C, Clonogenic assays were performed in mesenchymal-TNBC MDA-MB-231 (A) and 
BT-549 cells (B), as well as LAR-TNBC MDA-MB-453 cells (C). After 10nM miR-34a 
(red line) or miR-Scr (blue line) transfection, cells were plated at low cell densities in 0–
900nM dasatinib (left panels), or 0–4nM paclitaxel (right panels), and resultant colonies 
were counted 10 days later. Data are presented as the surviving fraction as relative to the 
0nM condition for each miRNA treatment condition. (D) qPCR assessment of miR-34a 
levels in dasatinib treated MDA-MB-231 cells for 60 hours. (E) miR-34a activity assays 
using a psiCheck2 3′UTR luciferase reporter in MDA-MB-231 cells. Cells were transfected 
with sensor constructs (WT=fully complementary miR-34a element (red), or a 
MUT=mutated miR-34a element (blue)) and treated with the indicated dasatinib doses for 
48hrs. (F) Dasatinib IC50 curves of MDA-MB-231-DasR cells (green line), dasatinib 
sensitive parental MDA-MB-231 cells (red line), and dasatinib insensitive MCF-7 cells 
(black line). (G) Clonogenic assays performed in MDA-MB-231-DasR cells, with indicated 
doses of dasatinib. (H) qPCR assessment of miR-34a levels in MDA-MB-231-DasR or 
parental cells either pulsed or maintained continuously in 100nM dasatinib for 60hrs. P-
values of clonogenic assays were calculated by two-way ANOVA. * Indicates p<0.05, as 
compared to control conditions.
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Figure 5. The proto-oncogene c-SRC is a target of miR-34a
A, Schematic depicting the human SRC 3′UTR using the indicated miRNA targeting 
algorithms, where blue boxes indicated conserved sites, and orange boxes are non-conserved 
sites. B, 3′UTR luciferase assays whereby 293T cells were co-transfected with either an 
Empty or full length SRC 3′UTR luciferase construct along with miRNA mimics at the 
doses as indicated. C–D, qPCR assessment of SRC mRNA levels (C) and western blot 
analysis of c-SRC expression (D) 72 hours post 10nM miR-34a transfection in the indicated 
cell lines. E, c-SRC mRNA levels from orthotopically implanted MDA-MB-231 tumors 
after miR-34a-tNP treatment. F, MDA-MB-231 cells transfected with 15nM si-SRC or si-
Neg control, and after 5 days cells were fixed and stained with crystal violet. G, 
Quantification of SA-β-gal activity in MDA-MB-231 cells 6 days post 15nM siRNA 
transfection. H–J, Characterization of siRNA transfected TNBC cells (15nM) by SRB 
growth assays (H), siRNA knockdown efficiency by western blot analysis (I) (Neg=si-Neg, 
and Si=si-SRC), and by assessment of miRNA levels via qPCR (J). In all experiments cells 
were transfected with 15nM siRNA, and assayed 72 hours post-transfection unless indicated 
otherwise. Values below each western blot represent the mean densitometric measurement 
of band intensities relative to the miR-Scr control treatment within each cell line. The 
numbers highlighted in red indicate SRC/β-actin ratios for each condition. * Indicates 
p<0.05, as compared to control conditions. P-values of SRB assays were calculated by two-
way ANOVA.
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Figure 6. c-SRC overexpression rescues miR-34a-induced phenotypes and is part of miR-34a 
gene signature
A, Western blot analysis measuring c-SRC, β-catenin, and GAPDH expression in c-SRC-
ORF (ORF), GFP-EMPTY (GFP), and parental (Par) MDA-MB-231 cell lines. Values 
below each blot represent the mean densitometric measurement. B–D, Characterization of 
SRC-ORF-based rescue experiments. For SRB growth assays, c-SRC-ORF (ORF) and GFP-
EMPTY (GFP) lines were transfected with 15nM miR-34a or miR-Scr control, and assayed 
at indicated time points (B). miR-34a transfected c-SRC-ORF (ORF) and GFP-EMPTY 
(GFP) lines at indicated doses were assayed for growth in soft agar (C), for invasion 
potential in Matrigel-Boyden chamber assays (D), and for miR-34a levels via qPCR 
analysis. E, Levels of miR-34 and miR-15a in c-SRC-ORF, GFP-EMPTY, and parental 
MDA-MB-231 cell lines. F, Heat map representing log2 transformed qPCR array data from 
TNBC cells 72 hours post-transfection with either 10nM miR-Scr or miR-34a. Data was 
normalized to the geometric mean of B2M and RPLP0 levels, and presented as Euclidean 
distance with average linkage using CIMminer. G, Table depicting a miR-34a gene 
signature consisting of 7 genes whose expression decreases 2-fold or more when treated 
with miR-34a, across three different TNBC cell lines. Data originated from qPCR breast 
cancer array experiments on RNA isolates 72hrs post miR-34a transfection. Values in table 
represent fold change in gene expression levels in each cell line relative to the miR-Scr 
control treatment. TS=TargetScan predicted site, (Score)=context score from TargetScan 
algorithm. H, Kaplan-Meier and Cox-regression analysis of the 7-gene miR-34a gene 
signature and overall survival in both Luminal-A (left panel) and TNBC (right panel) breast 
cancer patients from the KM-plotter Affymetrix array dataset(38). I, Diagram depicting the 
intersection of miR-34a and the c-SRC signaling pathway. Orange boxes indicate receptors, 
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green circles depict intracellular adaptor proteins and kinases, and SRC is highlighted in 
blue. Experimentally validated miR-34a targets are indicated by italicized green text. For 
brevity, particular signaling modules are shown as boxes containing keys genes within the 
pathway. * Indicates p<0.05, as compared to control conditions.
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